Integrum Valuation

Is INTEG B undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of INTEG B when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate INTEG B's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate INTEG B's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for INTEG B?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for INTEG B. This is calculated by dividing INTEG B's market cap by their current preferred multiple.
What is INTEG B's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	SEK 479.10m

INTEG B key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	4x
Enterprise Value/EBITDA	-109.2x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does INTEG B's PS Ratio compare to its peers?

The above table shows the PS ratio for INTEG B vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	19x
BRAIN BrainCool	10.1x	n/a	SEK 425.7m
ACARIX Acarix	62.7x	92.5%	SEK 392.3m
CRAD B C-Rad	2x	14.8%	SEK 990.6m
CARE Careium	0.9x	10.2%	SEK 790.6m
INTEG B Integrum	4.4x	29.7%	SEK 479.1m

Price-To-Sales vs Peers: INTEG B is good value based on its Price-To-Sales Ratio (4.4x) compared to the peer average (19x).

Price to Earnings Ratio vs Industry

How does INTEG B's PE Ratio compare vs other companies in the SE Medical Equipment Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	32.8%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	32.8%
	n/a	n/a	n/a

No more companies

Price-To-Sales vs Industry: INTEG B is good value based on its Price-To-Sales Ratio (4.4x) compared to the Swedish Medical Equipment industry average (4.6x).

Price to Sales Ratio vs Fair Ratio

What is INTEG B's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

INTEG B PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	4.4x
Fair PS Ratio	7.7x

Price-To-Sales vs Fair Ratio: INTEG B is good value based on its Price-To-Sales Ratio (4.4x) compared to the estimated Fair Price-To-Sales Ratio (7.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst INTEG B forecast and predictions for the stock price in 12 month’s time.
Date	Share Price	Average 1Y Price Target	Dispersion	High	Low	1Y Actual price	Analysts
Current	SEK 24.70	SEK 62.50 +153.0%	15.2%	SEK 72.00	SEK 53.00	n/a	2
Oct ’25	SEK 26.40	SEK 62.50 +136.7%	15.2%	SEK 72.00	SEK 53.00	n/a	2
Sep ’25	SEK 31.60	SEK 62.50 +97.8%	15.2%	SEK 72.00	SEK 53.00	n/a	2
Aug ’25	SEK 50.40	SEK 76.75 +52.3%	2.9%	SEK 79.00	SEK 74.50	n/a	2
Jul ’25	SEK 57.40	SEK 76.75 +33.7%	2.9%	SEK 79.00	SEK 74.50	n/a	2
Jun ’25	SEK 50.80	SEK 70.75 +39.3%	5.3%	SEK 74.50	SEK 67.00	n/a	2
May ’25	SEK 57.20	SEK 70.75 +23.7%	5.3%	SEK 74.50	SEK 67.00	n/a	2

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.